F
Farid Boulad
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 200
Citations - 9436
Farid Boulad is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 43, co-authored 192 publications receiving 8457 citations. Previous affiliations of Farid Boulad include NewYork–Presbyterian Hospital & Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.
Johannes F. Scheid,Hugo Mouquet,Beatrix Ueberheide,Ron Diskin,Florian Klein,Thiago Y. Oliveira,John Pietzsch,John Pietzsch,David Fenyö,Alexander Abadir,Klara Velinzon,Arlene Hurley,Sunnie Myung,Farid Boulad,Pascal Poignard,Pascal Poignard,Dennis R. Burton,Dennis R. Burton,Florencia Pereyra,Florencia Pereyra,David D. Ho,Bruce D. Walker,Bruce D. Walker,Bruce D. Walker,Michael S. Seaman,Pamela J. Bjorkman,Pamela J. Bjorkman,Brian T. Chait,Michel C. Nussenzweig,Michel C. Nussenzweig +29 more
TL;DR: Anti-HIV broadly neutralizing antibodies with similar specificities and modes of binding were found in multiple HIV-infected individuals, and cloned 576 new HIV antibodies from four unrelated individuals to determine whether they are part of a larger group of related molecules.
Journal ArticleDOI
Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation
Esperanza B. Papadopoulos,Marc Ladanyi,David Emanuel,Stephen Mackinnon,Farid Boulad,Matthew H. Carabasi,Hugo Castro-Malaspina,Barrett H. Childs,Alfred P. Gillio,Trudy N. Small,James W. Young,Nancy A. Kernan,Richard J. O'Reilly +12 more
TL;DR: In a small number of patients, infusions of unirradiated donor leukocytes were an effective treatment for EBV-associated lymphoproliferative disease that arose after allogeneic bone marrow transplantation.
Journal ArticleDOI
Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease
Stephen Mackinnon,Esperanza B. Papadopoulos,MH Carabasi,L Reich,Nancy H. Collins,Farid Boulad,Hugo Castro-Malaspina,Barrett H. Childs,Alfred P. Gillio,Nancy A. Kernan +9 more
TL;DR: The dose of donor leukocytes or T cells used may be important in determining both the GVL response and the incidence of GVHD, and 15 of the 17 evaluable patients have become BCR-ABL negative by PCR.
Journal ArticleDOI
Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation : Effect of patient age and donor leukocyte infusions
Trudy N. Small,Esperanza B. Papadopoulos,Farid Boulad,P Black,Hugo Castro-Malaspina,Barrett H. Childs,Nancy H. Collins,Alfred P. Gillio,Daniel J. George,Ann A. Jakubowski,Glenn Heller,Melissa Fazzari,Nancy A. Kernan,Stephen Mackinnon,Paul Szabolcs,James W. Young,R.J. O'Reilly +16 more
TL;DR: It is demonstrated that adult recipients of TCD unrelated BMTs experience prolonged and profound deficiencies of CD3(+, CD4(+), and CD8(+) T-cell populations when compared with pediatric recipients of unrelated B MT and adults after related BMT, and that these adults have a significantly increased risk of life-threatening opportunistic infections.
Journal ArticleDOI
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation
Ekaterina Doubrovina,Banu Oflaz-Sozmen,Susan E. Prockop,Nancy A. Kernan,Sara J. Abramson,Julie Teruya-Feldstein,Cyrus V. Hedvat,Joanne F. Chou,Glenn Heller,Juliet N. Barker,Farid Boulad,Hugo Castro-Malaspina,Diane George,Ann A. Jakubowski,Guenther Koehne,Esperanza B. Papadopoulos,Andromachi Scaradavou,Trudy N. Small,Ramzi Khalaf,James W. Young,Richard J. O'Reilly +20 more
TL;DR: Either unselected DLIs or EBV-specific CTLs can eradicate both untreated and Rituxan-resistant lymphomatousEBV-LPD, with failures ascribable to impaired T-cell recognition of tumor-associated viral antigens or their presenting HLA alleles.